Agents in development for prostate cancer prevention

Bibliography

• HSING AW, TSAO L, DEVESA SS: International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer (2000) 85:60–67.
   PubMed Web of Science ®Google Scholar
• HAENSZEL W, KURIHARA M: Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J. Nati Cancer Inst. (1968) 40:43–68.
   PubMed Web of Science ®Google Scholar
• WHITTEMORE AS, KOLONEL LN, WU AH et al.: Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J. Natl. Cancer Inst. (1995) 87:652–661.
   PubMed Web of Science ®Google Scholar
• SHIMIZU H, ROSS RK, BERNSTEIN L, YATANI R, HENDERSON BE, MACK TM: Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br. J. Cancer (1991) 63:963–966.
   PubMed Web of Science ®Google Scholar
• LICHTENSTEIN P, HOLM NV, VERKASALO PK et al.: Environmental and heritable factors in the causation of cancer- analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl. J. Med. (2000) 343:78–85.
   PubMed Web of Science ®Google Scholar
• CARTER BS, BEATY TH, STEINBERG GD, CHILDS B, WALSH PC: Mendelian inheritance of familial prostate cancer. Proc. Natl. Acad. Sci.USA (1992) 89:3367–3371.
   PubMed Web of Science ®Google Scholar
• •Key report of inherited susceptibility to prostate cancer development.
   Google Scholar
• SMITH JR, FREIJE D, CARPTEN JD et al.: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 274:1371–1374.
   PubMed Web of Science ®Google Scholar
• XU J, GILLANDERS EM, ISAACS SD et al.: Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. Prostate (2003) 57:320–325.
   PubMed Web of Science ®Google Scholar
• CARPTEN J, NUPPONEN N, ISAACS S et al.: Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat. Genet. (2002) 30:181–184.
   PubMed Web of Science ®Google Scholar
• ••Identification of RNASEL as a prostatecancer susceptibility gene.
   Google Scholar
• CASEY G, NEVILLE PJ, PLUMMER SJ et al: RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat. Genet. (2002) 32(4):581–583.
   PubMed Web of Science ®Google Scholar
• XU J, ZHENG SL, HAWKINS GA et al.: Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. Am. J. Hum. Genet. (2001) 69:341–350.
   PubMed Web of Science ®Google Scholar
• XU J, ZHENG SL, KOMIYA A et al.: Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat. Genet. (2002) 32:321–325.
   PubMed Web of Science ®Google Scholar
• ••Identification of MSR1 as a prostate cancersusceptibility gene.
   Google Scholar
• XU J, ZHENG SL, KOMIYA A et al.: Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am. J. Hum. Genet. (2003) 72:208–212.
   PubMed Web of Science ®Google Scholar
• SILVERMAN RH, JUNG DD, NOLAN-SORDEN NL, DIEFFENBACH CW, KEDAR VP, SENGUPTA DN: Purification and analysis of murine 2-5A-dependent RNase. j Biol. Chem. (1988) 263:7336–7341.
   PubMed Web of Science ®Google Scholar
• JACOBSEN H, CZARNIECKI CW, KRAUSE D, FRIEDMAN RM, SILVERMAN RH: Interferon-induced synthesis of 2-5A-dependent RNase in mouse JLS-V9R cells. Virology(1983) 125:496–501.
   PubMed Web of Science ®Google Scholar
• FLOYD-SMITH G, SLATTERY E, LENGYEL P: Interferon action: RNA cleavage pattern of a (2'-51 oligoadenylate-dependent endonuclease. Science (1981) 212:1030–1032.
   PubMed Web of Science ®Google Scholar
• CLEMENS MJ, WILLIAMS BR: Inhibition of cell-free protein synthesis by pppA2'135'A45'A: a novel oligonucleotide synthesized by interferon-treated L cell extracts. Cell (1978) 13:565–572.
   PubMed Web of Science ®Google Scholar
• ZHOU A, HASSEL BA, SILVERMAN RH: Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell (1993) 72:753–765.
   PubMed Web of Science ®Google Scholar
• PLATT N, GORDON S: Is the class A macrophage scavenger receptor (SR-A) multifunctional? - The mouse's tale. j Chi]. Invest. (2001) 108:649–654.
   PubMed Web of Science ®Google Scholar
• ZHOU A, PARANJAPE J, BROWN TL et al.: Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. EMBO J. (1997) 16:6355–6363.
   PubMed Web of Science ®Google Scholar
• SUZUKI H, KURIHARA Y, TAKEYA M et al.: A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature (1997) 386:292–296.
   PubMed Web of Science ®Google Scholar
• PEISER L, GOUGH PJ, KODAMA T, GORDON S: Macrophage class A scavenger receptor-mediated phagocytosis of Escherichia coli: role of cell heterogeneity, microbial strain, and culture conditions in vitro. Infect. Inman. (2000) 68:1953–1963.
   PubMed Web of Science ®Google Scholar
• THOMAS CA, LI Y, KODAMA T, SUZUKI H, SILVERSTEIN SC, EL KHOURY J: Protection from lethal Gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J. Exp. Med. (2000) 191:147–156.
   PubMed Web of Science ®Google Scholar
• PLATZ EA, DE MARZO AM: Epidemiology of inflammation and prostate cancer. Um]. (2004) 171:S36–S40.
   Google Scholar
• •Review of epidemiology linking prostate inflammation and prostate cancer.
   Google Scholar
• GARDNER WA, BENNETT BD: The prostate overview: recent insights and speculations. In: Pathology, and Pathobiology of the Urinary Bladder and Prostate. RS Weinstein, WA Garnder (Eds), Williams and Wilkens, Baltimore, USA (1992):129–148.
   Google Scholar
• ROBERTS RO, LIEBER MM, RHODES T, GIRMAN CJ, BOST WICK DG, JACOBSEN SJ: Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology (1998) 51:578–584.
   PubMed Web of Science ®Google Scholar
• CARVER BS, BOZEMAN CB, WILLIAMS BJ, VENABLE DD: The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. J. Um]. (2003) 169:589–591.
   Web of Science ®Google Scholar
• KRIEGER JN, RILEY DE, ROBERTS MC, BERGER RE: Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. Clin. Microbiol (1996) 34:3120–3128.
   Web of Science ®Google Scholar
• KRIEGER JN, RILEY DE: Prostatitis: what is the role of infection. Int. J. Antimicrob. Agents (2002) 19:475–479.
   PubMed Web of Science ®Google Scholar
• HOEKX L, JEURIS W, VAN MARCK E, WYNDAELE JJ: Elevated serum prostate specific antigen (PSA) related to asymptomatic prostatic inflammation. Acta Um]. Belg. (1998) 66:1–2.
   PubMedGoogle Scholar
• GERSTENBLUTH RE, SEFTEL AD, MacLENNAN GT et al.: Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bc1-2 in areas of inflammation. J. Ura (2002) 167:2267–2270.
   Google Scholar
• DENNIS LK, LYNCH CE TORNER JC: Epidemiologic association between prostatitis and prostate cancer. Urology (2002) 60:78–83.
   PubMed Web of Science ®Google Scholar
• DE MARZO AM, MARCHI VL, EPSTEIN JI, NELSON WG: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol (1999) 155:1985–1992.
   PubMed Web of Science ®Google Scholar
• ••Evidence that an inflammatory lesion inthe prostate, PIA, is a precursor to prostate cancer.
   Google Scholar
• FRANKS LM: Atrophy and hyperplasia inthe prostate proper. J. Pathol Bacteria (1954)68:617–621.
   Google Scholar
• FENELEY MR, YOUNG MP, CHINYAMA C, KIRBY RS, PARKINSON MC: Ki-67 expression in early prostate cancer and associated pathological lesions. Clin. Pathol (1996) 49:741–748.
   PubMed Web of Science ®Google Scholar
• RUSKA KM, SAUVAGEOT J, EPSTEIN JI: Histology and cellular kinetics of prostatic atrophy. Am. I. Sag. Pathol (1998) 22:1073–1077.
   PubMed Web of Science ®Google Scholar
• PUTZI MJ, DE MARZO AM: Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology(2000) 56:828–832.
   PubMed Web of Science ®Google Scholar
• NAKAYAMA M, BENNETT CJ, HICKS JL et al.: Hypermethylation of the human glutathione ..Ctransferase-pi gene (CSTPI) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Patha (2003) 163:923–933.
   Google Scholar
• •A fraction of PIA lesions have somatic genome alterations in common with prostate cancer.
   Google Scholar
• SHAH R, MUCCI NR, AMIN A, MACOSKA JA, RUBIN MA: Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am. J. Patha (2001) 158:1767–1773.
   PubMed Web of Science ®Google Scholar
• SHURBAJI MS, GUPTA PK, MYERS J: Immunohistochemical demonstration of Chlamydial antigens in association with prostatitis. Mod. Patha (1988) 1:348–351.
   PubMed Web of Science ®Google Scholar
• PARSONS JK, NELSON CP, GAGE WR, NELSON WG, KENSLER TW, DE MARZO AM: GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate (2001) 49:30–37.
   PubMed Web of Science ®Google Scholar
• ZHA S, GAGE WR, SAUVAGEOT J et al.: Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. (2001) 61:8617–8623.
   PubMed Web of Science ®Google Scholar
• ••COX-2, a major prostate cancer preventiondrug target, is expressed selectively in PIA lesions.
   Google Scholar
• GONZALGO ML, ISAACS WB: Molecular pathways to prostate cancer. Ura (2003) 170:2444–2452.
   PubMed Web of Science ®Google Scholar
• YEGNASUBRAMANIAN S, KOWALSKI J, GONZALGO ML et al.: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. (2004) 64:1975–1986.
   PubMed Web of Science ®Google Scholar
• LEE WH, MORTON RA, EPSTEIN JI et al.: Cytidine methylation of regulatory sequences near the pi-class glutathione ..Ctransferase gene accompanies human prostatic carcinogenesis. Proc. Nati Acad. Sci. USA (1994) 91: 11733-11737.
   Google Scholar
• LIN X, TASCILAR M, LEE WH et al.: GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Patha (2001) 159:1815–1826.
   PubMed Web of Science ®Google Scholar
• ••A detailed molecular pathology analysis ofthe most common somatic genome alteration in prostate cancer cells.
   Google Scholar
• BROOKS JD, WEINSTEIN M, LIN X et al.: CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemia Biomarkers Prey (1998) 7:531–536.
   PubMed Web of Science ®Google Scholar
• DEVVEESE TL, NELSON WG: Inadequate 'caretaker' gene function and human cancer development. Methods Ma Biol. (2003) 222:249–268.
   PubMedGoogle Scholar
• HENDERSON CJ, SMITH AG, URE J, BROWN K, BACON EJ, WOLF CR: Increased skin tumorigenesis in mice lacking pi class glutathione ..Ctransferases. Proc. Natl. Acad. Sci. USA (1998) 95:5275–5280.
   PubMed Web of Science ®Google Scholar
• NELSON CP, KIDD LC, SAUVAGEOT J et al.: Protection against 2-hydroxyamino-1-methyl-6 -phenylimidazo [4,5- bl pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione ..Ctransferase Pl. Cancer Res. (2001) 61:103–109.
   Google Scholar
• SHIRAI T, SANO M, TAMANO S et al: The prostate: a target for carcinogenicity of 2-amino- 1-methyl-6- phenylimidazo [4,5- blpyridine (PhIP) derived from cooked foods. Cancer Res. (1997) 57:195–198.
   PubMed Web of Science ®Google Scholar
• NELSON WG, DE MARZO AM, ISAACS WB: Prostate cancer. N Engl. J. Med. (2003) 349:366–381.
   PubMed Web of Science ®Google Scholar
• ••Review of the molecular pathogenesis ofprostate cancer.
   Google Scholar
• BRUCHOVSKY N, WILSON JD: The conversion of testosterone to 5-a-androstan 17 13 ol 3 one by rat prostate in vivo and M vitro. I. Biol. Chem. (1968) 243:2012–2021.
   Web of Science ®Google Scholar
• CHANG CS, KOKONTIS J, LIAO ST: Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science (1988) 240:324–326.
   PubMed Web of Science ®Google Scholar
• ROCHE PJ, HOARE SA, PARKER MG: A consensus DNA-binding site for the androgen receptor. Ma. Endocrina (1992) 6:2229–2235.
   PubMed Web of Science ®Google Scholar
• SCHUUR ER, HENDERSON GA, KMETEC LA, MILLER JD, LAMPARSKI HG, HENDERSON DR: Prostate-specific antigen expression is regulated by an upstream enhancer. Biol. Chem. (1996) 271:7043–7051.
   Web of Science ®Google Scholar
• FELDMAN BJ, FELDMAN D: The development of androgen-independent prostate cancer. Nat. Rey Cancer (2001) 1:34–45.
   PubMed Web of Science ®Google Scholar
• ••Review of androgen signalling in theprostate and the emergence of androgen-independent prostate cancer during androgen deprivation therapy.
   Google Scholar
• SUGIMURA Y, CUNHA GR, BIGSBY RM: Androgenic induction of DNA synthesis in prostatic glands induced in the urothelium of testicular feminised (Tfm/Y) mice. Prostate (1986) 9:217–225.
   PubMed Web of Science ®Google Scholar
• CUNHA GR, CHUNG LW: Stromal-epithelial interactions-I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. Steroid. Biochem. (1981) 14:1317–1324.
   Google Scholar
• PEEHL DM, RUBIN JS: Keratinocyte growth factor: an androgen-regulated mediator of stromal-epithelial interactions in the prostate. World Ura (1995) 13:312–317.
   PubMed Web of Science ®Google Scholar
• PLANZ B, WANG Q, KIRLEY SD, LIN CW, McDOUGAL WS: Androgen responsiveness of stromal cells of the human prostate: regulation of cell proliferation and keratinocyte growth factor by androgen. Ura (1998) 160:1850–1855.
   PubMed Web of Science ®Google Scholar
• LU W, LUO Y, KAN M, McKEEHAN WL: Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. Biol Chem. (1999) 274:12827–12834.
   Google Scholar
• WU X, JIN C, WANG F, YU C, McKEEHAN WL: Stromal cell heterogeneity in fibroblast growth factor-mediated stromal-epithelial cell cross-talk in premalignant prostate tumors. Cancer Res. (2003) 63:4936–4944.
   PubMed Web of Science ®Google Scholar
• MARKER PC, DONJACOUR AA, DAHIYA R, CUNHA GR: Hormonal, cellular, and molecular control of prostatic development. Dev. Biol. (2003) 253:165–174.
   PubMed Web of Science ®Google Scholar
• DE MARZO AM, NELSON WG, MEEKER AK, COFFEY DS: Stem cell features of benign and malignant prostate epithelial cells. J. Urol. (1998) 160:2381–2392.
   PubMed Web of Science ®Google Scholar
• SAKR WA, GRIGNON DJ, CRISSMAN JD et al.: High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. hi Vivo (1994) 8:439–443.
   PubMedGoogle Scholar
• STANBROUGH M, LEAV I, KWAN PW, BUBLEY GJ, BALK SP: Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc. Natl. Acad. &L USA (2001) 98:10823–10828.
   PubMed Web of Science ®Google Scholar
• BOSLAND MC: Animal models for the study of prostate carcinogenesis. J. Biochem. Suppl. (1992) 16H:89–98.
   PubMedGoogle Scholar
• BOSLAND MC: The role of steroid hormones in prostate carcinogenesis. J. Natl. Cancer Inst. Monogr (2000) 27:39–66.
   PubMedGoogle Scholar
• HUGGINS C, STEVENS RE, HODGES CV: Studies on prostate cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. (1941) 43:209–222.
   Google Scholar
• EISENBERGER MA, BLUMENSTEIN BA, CRAWFORD ED et al.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. (1998) 339:1036–1042.
   PubMed Web of Science ®Google Scholar
• PARTIN AW, HANKS GE, KLEIN EA, MOUL JW, NELSON WG, SCHER HI: Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology (2002) 16:1024–1038.
   PubMed Web of Science ®Google Scholar
• PARTIN AW, HANKS GE, KLEIN EA, MOUL JW, NELSON WG, SCHER HI: Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology (2002) 16:1218–1224.
   PubMed Web of Science ®Google Scholar
• TAPLIN ME, BUBLEY GJ, SHUSTER TD et al.: Mutation of the androgen-receptor gene in metastatic androgen- independent prostate cancer. N Engl. J. Med. (1995) 332:1393–1398.
   PubMed Web of Science ®Google Scholar
• CRAFT N, SHOSTAK Y, CAREY M, SAWYERS CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. (1999) 5:280–285.
   PubMed Web of Science ®Google Scholar
• HOBISCH A, EDER IE, PUTZ T et al: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. (1998) 58:4640–4645.
   PubMed Web of Science ®Google Scholar
• NAZARETH LV, VVEIGEL NL: Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem. (1996) 271:19900–19907.
   PubMed Web of Science ®Google Scholar
• CHEN CD, VVELSBIE DS, TRAN C et al.: Molecular determinants of resistance to antiandrogen therapy. Nat. Med. (2004) 10:33–39.
   PubMed Web of Science ®Google Scholar
• RUSSELL DW, WILSON JD: Steroid 5 a-reductase: two genes/two enzymes. Ann. Rev Biochem (1994) 63:25–61.
   PubMed Web of Science ®Google Scholar
• ••Review of 5a-reductases.
   Google Scholar
• BRUCHOVSKY N, SADAR MD, AKAKURA K, GOLDENBERG SL, MATSUOKA K, RENNIE PS: Characterization of 5a-reductase gene expression in stroma and epithelium of human prostate." Steroid Biochem. Mol. Biol. (1996) 59:397–404.
   PubMed Web of Science ®Google Scholar
• THIGPEN AE, SILVER RI, GUILEYARDO JM, CASEY ML, McCONNELL JD, RUSSELL DW: Tissue distribution and ontogeny of steroid 5 a-reductase isozyme expression. Chu. Invest. (1993) 92:903–910.
   PubMed Web of Science ®Google Scholar
• MAKRIDAKIS NM, DI SALLE E, REICHARDT JK: Biochemical and pharmacogenetic dissection of human steroid 5a-reductase Type II. Pharmacogenetics (2000) 10:407–413.
   PubMedGoogle Scholar
• MAKRIDAKIS NM, ROSS RK, PIKE MC et al.: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet (1999) 354:975–978.
   PubMed Web of Science ®Google Scholar
• ALLEN NE, REICHARDT JK, NGUYEN H, KEY TJ: Association between two polymorphisms in theSRD5A2 gene and serum androgen concentrations in British men. Cancer Epidemiol. Biomarkers Prey (2003) 12:578–581.
   PubMed Web of Science ®Google Scholar
• LUO J, DUNN TA, EWING CM, WALSH PC, ISAACS WB: Decreased gene expression of steroid 5a-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate (2003) 57:134–139.
   PubMed Web of Science ®Google Scholar
• THOMAS LN, DOUGLAS RC, VESSEY JP et al.: 5a-reductase Type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. Urol. (2003)170:2019-2025.
   Google Scholar
• TIAN G, MOOK RA, JR, MOSS ML, FRYE SV: Mechanism of time-dependent inhibition of 5a-reductases by 81-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry (1995) 34:13453–13459.
   PubMed Web of Science ®Google Scholar
• FRYE SV, BRAMSON HN, HERMANN DJ, LEE FW, SINHABABU AK, TIAN G: Discovery and development of GG745, a potent inhibitor of both isozymes of 5a-reductase. Pharm. Biotechnol. (1998) 11:393–422.
   PubMedGoogle Scholar
• RITTMASTER RS, STONER E, THOMPSON DL, NANCE D, LASSETER KC: Effect of MK-906, a specific 5a-reductase inhibitor, on serum androgens and androgen conjugates in normal men. Andra (1989) 10:259–262.
   PubMed Web of Science ®Google Scholar
• CLARK RV, HERMANN DJ, CUNNINGHAM GR, WILSON TH, MORRILL BB, HOBBS S: Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5a-reductase inhibitor. J. Clio. Endocrinol. Metab (2004) 89:2179–2184.
   PubMed Web of Science ®Google Scholar
• GORMLEY GJ, STONER E, BRUSKEWITZ RC et al.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N. Engl. J. Med. (1992) 327:1185–1191.
   PubMed Web of Science ®Google Scholar
• McCONNELL JD, ROEHRBORN CG, BAUTISTA OM et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl. J. Med. (2003) 349:2387–2398.
   PubMed Web of Science ®Google Scholar
• McCONNELL JD, BRUSKEWITZ R, WALSH P et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia.
   Google Scholar
• •• Finasteride Long-Term Efficacy and Safety Study Group. N Engl. I Med. (1998) 338:557–563.
   Google Scholar
• PRESTI JC, JR, FAIR WR, ANDRIOLE G et al.: Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer.' Urol. (1992) 148:1201–1204.
   PubMed Web of Science ®Google Scholar
• ANDRIOLE G, LIEBER M, SMITH J et al.: Treatment with finasteride following radical prostatectomy for prostate cancer. Urology (1995) 45:491–497.
   PubMed Web of Science ®Google Scholar
• TSUKAMOTO S, AKAZA H, IMADA S et al.: Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. Natl. Cancer Inst. (1995) 87:842–843.
   Google Scholar
• HOMMA Y, KANEKO M, KONDO Y, KAWABE K, KAKIZOE T: Inhibition of rat prostate carcinogenesis by a 5a-reductase inhibitor, EK143.1 Nati Cancer Inst. (1997) 89:803–807.
   PubMed Web of Science ®Google Scholar
• ESMAT AY, REFAIE FM, SHAHEEN MH, SAID MM: Chemoprevention of prostate carcinogenesis by DEMO and/or finasteride treatment in male Wistar rats. Turnori (2002) 88:513–521.
   Google Scholar
• SEO SI, LEE SJ, KIM JC et al.: Effects of androgen deprivation on chronic bacterial prostatitis in a rat model. Int. .1. Urol. (2003) 10:485–491.
   Google Scholar
• THOMPSON IM, GOODMAN PJ, TANGEN CM et al.: The influence of finasteride on the development of prostate cancer. N Engl. Med. (2003) 349:215–224.
   PubMed Web of Science ®Google Scholar
• ••Results of the Phase III clinical trial offinasteride for prostate cancer prevention.
   Google Scholar
• BOSTWICK DG, QIAN J, CIVANTOS F, ROEHRBORN CG, MONTIRONI R: Does finasteride alter the pathology of the prostate and cancer grading? Clin. Prostate Cancer (2004) 2:228–235.
   Google Scholar
• •Description of the controversy over prostate cancer grading in the setting of finasteride use.
   Google Scholar
• ROEHRBORN CG, BOYLE P, NICKEL JC, HOEFNER K, ANDRIOLE G: Efficacy and safety of a dual inhibitor of 5a-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology (2002) 60:434–441.
   PubMed Web of Science ®Google Scholar
• HUSSAIN SP, HOFSETH LJ, HARRIS CC: Radical causes of cancer. Nat. Rev Cancer (2003) 3:276–285.
   PubMed Web of Science ®Google Scholar
• MALINS DC, JOHNSON PM, WHEELER TM, BARKER EA, POLISSAR NL, VINSON MA: Age-related radical-induced DNA damage is linked to prostate cancer. Cancer Res. (2001) 61:6025–6028.
   PubMed Web of Science ®Google Scholar
• BOSTWICK DG, ALEXANDER EE, SINGH R et al.: Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer (2000) 89:123–134.
   PubMed Web of Science ®Google Scholar
• RIPPLE MO, HENRY WF, RAGO RP, WILDING G: Prowddant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells [see comments]. Nati Cancer Inst. (1997) 89:40–48.
   PubMed Web of Science ®Google Scholar
• RIPPLE MO, HENRY WF, SCHWARZE SR, WILDING G, WEINDRUCH R: Effect of antioxidants on androgen-induced AP-1 and NE-icB DNA- binding activity in prostate carcinoma cells. Natl. Cancer Inst. (1999) 91:1227–1232.
   Google Scholar
• XU J, ZHENG SL, TURNER A et al: Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res. (2002) 62:2253–2257.
   PubMed Web of Science ®Google Scholar
• WOODSON K, TANGREA JA, LEHMAN TA et al: Manganese superoxide dismutase (MnSOD) polymorphism, a-tocopherol supplementation and prostate cancer risk in the a-tocopherol, I3-carotene cancer prevention study (Finland). Cancer Causes Control (2003) 14:513–518.
   PubMed Web of Science ®Google Scholar
• BROOKS JD, METTER EJ, CHAN DW et al.: Plasma selenium level before diagnosis and the risk of prostate cancer development. Urol. (2001) 166:2034–2038.
   Web of Science ®Google Scholar
• LI H, STAMPFER MJ, GIOVANNUCCI EL et al.: A prospective study of plasma selenium levels and prostate cancer risk. Natl. Cancer Inst. (2004) 96:696–703.
   Google Scholar
• VAN DEN BRANDT PA, ZEEGERS MP, BODE P, GOLDBOHM RA: Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epiderniol. Biomarkers Prey (2003) 12:866–871.
   PubMed Web of Science ®Google Scholar
• HELZLSOUER KJ, HUANG HY, ALBERG AJ et al.: Association between a-tocopherol, y-tocopherol, selenium, and subsequent prostate cancer. Nati Cancer Inst. (2000) 92:2018–2023.
   PubMed Web of Science ®Google Scholar
• NOMURA AM, LEE J, STEMMERMANN GN, COMBS GF Jr: Serum selenium and subsequent risk of prostate cancer. Cancer Epiderniol. Biomarkers Prey (2000) 9:883–887.
   PubMed Web of Science ®Google Scholar
• YOSHIZAWA K, WILLETT WC, MORRIS SJ et al.: Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. Nati Cancer Inst. (1998) 90:1219–1224.
   PubMed Web of Science ®Google Scholar
• WILLETT WC, POLK BE MORRIS JS et al.: Prediagnostic serum selenium and risk of cancer. Lancet (1983) 2:130–134.
   Google Scholar
• HARDELL L, DEGERMAN A, TOMIC R, MARKLUND SL, BERGFORS M: Levels of selenium in plasma and glutathione peroxidase in erythrocytes in patients with prostate cancer or benign hyperplasia. LPL J. Cancer Prey (1995) 4:91–95.
   PubMed Web of Science ®Google Scholar
• CLARK LC, COMBS GF JR, TURNBULL BW et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group (1996) 276:1957–1963.
   Google Scholar
• CLARK LC, DALKIN B, KRONGRAD A et al.: Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br.j Urol. (1998) 81:730–734.
   PubMedGoogle Scholar
• DUFFIELD-LILLICO AJ, DALKIN BL, REID ME et al.: Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. RIU Int. (2003) 91:608–612.
   Google Scholar
• ••Results of a Phase III clinical trial showingselenium supplementation decreases prostate cancer incidence.
   Google Scholar
• HUANG HY, ALBERG AJ, NORKUS EP, HOFFMAN SC, COMSTOCK GW, HELZLSOUER KJ: Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am. Epiderniol. (2003) 157:335–344.
   PubMed Web of Science ®Google Scholar
• EICHHOLZER M, STAHELIN HB, GEY KF, LUDIN E, BERNASCONI F: Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int. J. Cancer (1996) 66:145–150.
   PubMed Web of Science ®Google Scholar
• THE a-TOCOPHEROL, B-CAROTENE CANCER PREVENTION STUDY GROUP: The effect of vitamin E and I3-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl. Med. (1994) 330:1029–1035.
   PubMed Web of Science ®Google Scholar
• HEINONEN OP, ALBANES D, VIRTAMO J et al.: Prostate cancer and supplementation with a-tocopherol and I3-carotene: incidence and mortality in a controlled trial [see comments]. J. Nati Cancer Inst. (1998) 90:440–446.
   PubMed Web of Science ®Google Scholar
• ••Results of a Phase III clinical trial showingvitamin E supplementation decreases prostate cancer incidence.
   Google Scholar
• CHAN JM, STAMPFER MJ, MA J, RIMM EB, WILLETT WC, GIOVANNUCCI EL: Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prey (1999) 8:893–899.
   PubMed Web of Science ®Google Scholar
• KLEIN EA, THOMPSON IM, LIPPMAN SM et al.: SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J. Um]. (2001) 166:1311–1315.
   Google Scholar
• MEUILLET E, STRATTON S, PRASAD CHERUKURI D et al.: Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. I Cell. Biochem. (2004) 91:443–458.
   Google Scholar
• PATTERSON BH, LEVANDER OA: Naturally occurring selenium compounds in cancer chemoprevention trials: a workshop summary. Cancer Epidemiol. Biomarkers Prey. (1997) 6:63–69.
   PubMed Web of Science ®Google Scholar
• DRISCOLL DM, COPELAND PR: Mechanism and regulation of selenoprotein synthesis. Ann. Rev Num. (2003) 23:17–40.
   PubMed Web of Science ®Google Scholar
• KARUNASINGHE N, RYAN J, TUCKEY J et al.: DNA stability and serum selenium levels in a high-risk group for prostate cancer. Cancer Epidenhol. Biomarkers Prey (2004) 13:391–397.
   PubMed Web of Science ®Google Scholar
• CHAN JM, GIOVANNUCCI EL: Vegetables, fruits, associated micronutrients, and risk of prostate cancer. Epidenhol Rev (2001) 23:82–86.
   PubMed Web of Science ®Google Scholar
• GIOVANNUCCI E, ASCHERIO A, RIMM EB, STAMPFER MJ, COLDITZ GA, WILLETT WC: Intake of carotenoids and retinol in relation to risk of prostate cancer. Natl. Cancer Inst. (1995) 87:1767–1776.
   Google Scholar
• GIOVANNUCCI E, RIMM EB, LIU Y, STAMPFER MJ, WILLETT WC: A prospective study of tomato products, lycopene, and prostate cancer risk. J. Natl. Cancer Inst. (2002) 94:391–398.
   PubMed Web of Science ®Google Scholar
• GANN PH, MA J, GIOVANNUCCI E et al.: Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. (1999) 59:1225–1230.
   PubMed Web of Science ®Google Scholar
• LAVELLI V, PERT C, RIZZOLO A: Antioxidant activity of tomato products as studied by model reactions using xanthine oxidase, myeloperoxidase, and copper-induced lipid perwddation. I 41c. Food Chem. (2000) 48:1442–1448.
   PubMed Web of Science ®Google Scholar
• CHEN L, STACEWICZ-SAPUNTZAKIS M, DUNCAN C et al.: Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J. Natl. Cancer Inst. (2001) 93:1872–1879.
   PubMed Web of Science ®Google Scholar
• COHEN JH, KRISTAL AR, STANFORD JL: Fruit and vegetable intakes and prostate cancer risk. J. Nati Cancer Inst. (2000) 92:61–68.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, KENSLER TW, CHO CG, POSNER GH, TALALAY P: Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc. Natl. Acad. Sci. USA (1994) 91:3147–3150.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, TALALAY P, CHO CG, POSNER GH: A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. ScL USA (1992) 89:2399–2403.
   PubMed Web of Science ®Google Scholar
• DINKOVA-KOSTOVA AT, TALALAY P: Persuasive evidence that quinone reductase Type 1 (DT diaphorase) protects cells against the toxicity of electrophiles and reactive forms of oxygen. Free Radic. Biol. Med. (2000) 29:231–240.
   PubMed Web of Science ®Google Scholar
• DINKOVA-KOSTOVA AT, HOLTZCLAW WD, COLE RN et al: Direct evidence that sulfhydryl groups of Keapl are the sensors regulating induction of Phase II enzymes that protect against carcinogens and oxidants. Proc. Nati Acad. Sci. USA (2002) 99:11908–11913.
   PubMed Web of Science ®Google Scholar
• MILLER DC, ZHENG SL, DUNN RL et al.: Germ-line mutations of the macrophage scavenger receptor 1 gene: association with prostate cancer risk in African-American men. Cancer Res. (2003) 63:3486–3489.
   PubMed Web of Science ®Google Scholar
• LINDMARK F, ZHENG SL, WIKLUND F et al.: H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. Natl. Cancer Inst. (2004) 96:1248–1254.
   Google Scholar
• ZHENG SL, AUGUSTSSON-BALTER K, CHANG B et al.: Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res. (2004) 64:2918–2922.
   PubMed Web of Science ®Google Scholar
• BASLER JW, PIAZZA GA: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. Urol. (2004) 171:S59–S62.
   Google Scholar
• VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. (1971) 231:232–235.
   PubMedGoogle Scholar
• MASFERRER JL, SEIBERT K, ZWEIFEL B, NEEDLEMAN P: Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc. Nati Acad. Sci. USA (1992) 89:3917–3921.
   PubMed Web of Science ®Google Scholar
• OSHIMA M, DINCHUK JE, KARGMAN SL et al.: Suppression of intestinal polyposis in Apc 8716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell (1996) 87:803–809.
   PubMed Web of Science ®Google Scholar
• CHULADA PC, THOMPSON MB, MAHLER JF et al.: Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. (2000) 60:4705–4708.
   PubMed Web of Science ®Google Scholar
• GUPTA S, ADHAMI VM, SUBBARAYAN M et al.: Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. (2004) 64:3334–3343.
   PubMed Web of Science ®Google Scholar
• NARAYANAN BA, CONDON MS, BOSLAND MC, NARAYANAN NK, REDDY BS: Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clio. Cancer Res. (2003) 9:3503–3513.
   PubMed Web of Science ®Google Scholar
• HEATH El, DEVVEESE TL, PARTIN AW et al.: The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate. Clio. Prostate Cancer (2002) 1:182–187.
   PubMedGoogle Scholar
• ALBERT MA, DANIELSON E, RIFAI N, RIDKER PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 286:64–70.
   PubMed Web of Science ®Google Scholar
• SHISHEHBOR MH, AVILES RJ, BRENNAN ML et al.: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JA/VIA (2003) 289:1675–1680.
   Web of Science ®Google Scholar
• KISLEY LR, BARRETT BS, BAUER AK et al.: Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res. (2002) 62:6850–6856.
   PubMed Web of Science ®Google Scholar
• RAO CV, INDRANIE C, SIMI B, MANNING PT, CONNOR JR,
   Google Scholar
• AHN B, OHSHIMA H: Suppression of intestinal polyposis in Apc(Min/1 mice by inhibiting nitric oxide production. Cancer Res. (2001) 61:8357–8360.
   PubMed Web of Science ®Google Scholar
• NELSON WG, WILDING G: Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents. Urology (2001) 57:56–63.
   PubMed Web of Science ®Google Scholar
• • Review of prostate cancer prevention drug pipeline.
   Google Scholar
• DJAVAN B, ZLOTTA A, SCHULMAN C et al.: Chemotherapeutic prevention studies of prostate cancer. J. Urol. (2004) 171:S10–S13.
   PubMedGoogle Scholar
• • Another review of prostate cancer prevention drug pipeline.
   Google Scholar
• PREVENTION OF CANCER IN THE NEXT MILLENNIUM: Report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res. (1999) 59:4743–4758.
   PubMed Web of Science ®Google Scholar
• CHAN JM, STAMPFER MJ, GIOVANNUCCI E et al.: Plasma insulinlike growth factor-I and prostate cancer risk: a prospective study. Science (1998) 279:563–566.
   PubMed Web of Science ®Google Scholar
• GANN PH, HENNEKENS CH, STAMPFER MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 273:289–294.
   PubMed Web of Science ®Google Scholar
• ROSS KS, CARTER HB, PEARSON JD, GUESS HA: Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA (2000) 284:1399–1405.
   PubMed Web of Science ®Google Scholar
• PETRICOIN EF, ARDEKANI AM, HITT BA et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 359:572–527.
   PubMed Web of Science ®Google Scholar
• O'SHAUGHNESSY JA, KELLOFF GJ, GORDON GB et al: Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res. (2002) 8:314–346.
   PubMed Web of Science ®Google Scholar
• BABAIAN RJ, TOI A, KAMOI K et al: A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. Urol. (2000) 163:152–157.
   Web of Science ®Google Scholar
• TERRIS MK: Extended field prostate biopsies: too much of a good thing? Urology (2000) 55:457–460.
   PubMed Web of Science ®Google Scholar